HIV status doesn't influence Hodgkin's lymphoma outcome

October 11, 2012
HIV status doesn't influence hodgkin's lymphoma outcome
Despite more extensive disease and more adverse prognostic factors, HIV-positive patients with Hodgkin's lymphoma do not have worse outcomes when treated with doxorubicin, bleomycin, vinblastine, and dacarbazine, according to research published online Oct. 8 in the Journal of Clinical Oncology.

(HealthDay)—Despite more extensive disease and more adverse prognostic factors, HIV-positive patients with Hodgkin's lymphoma (HL) do not have worse outcomes when treated with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), according to research published online Oct. 8 in the Journal of Clinical Oncology.

Silvia Montoto, M.D., of the Queen Mary University of London, and colleagues conducted a study involving 224 patients with newly diagnosed HL, of whom 93 were HIV positive, who were treated with ABVD. The HIV-positive patients had more high-risk disease; 47 had CD4 counts below 200/µL and 92 received highly (HAART) during chemotherapy.

The researchers found that the complete response rate was not significantly different for HIV-positive and HIV-negative patients (74 and 79 percent, respectively). After a median follow-up of 60 months, 16 HIV-negative and seven HIV-positive patients had relapsed at a median of six months. Neither the five-year event-free survival rate (59 and 66 percent for positive and negative patients, respectively) nor the five-year overall survival rate (81 and 88 percent for positive and negative patients, respectively) were significantly different.

"In summary, this study consolidates the increasingly prevalent notion that, in the current HAART era, patients with HIV and lymphoma should be treated with the same protocols used in HIV-negative patients," the authors write. "As a corollary, should be removed from the exclusion criteria for entry onto clinical trials."

Several authors disclosed to the pharmaceutical industry.

Explore further: Standard treatments for head and neck cancer less effective in HIV-positive patients

More information: Abstract
Full Text (subscription or payment may be required)
Editorial

Related Stories

Standard treatments for head and neck cancer less effective in HIV-positive patients

January 26, 2012
Radiation therapy with or without chemotherapy is less effective for patients with HIV when compared to the recurrence and overall survival rates in patients who do not have HIV, according to a study presented at the Multidisciplinary ...

Bevacizumab active in HIV-linked Kaposi's sarcoma

March 20, 2012
(HealthDay) -- For patients with HIV-associated Kaposi's sarcoma (HIV-KS), bevacizumab is tolerated and induces a response in some patients, according to a study published online March 19 in the Journal of Clinical Oncology.

Mayo Clinic makes kidney and pancreas transplant available to HIV-infected patients

December 6, 2011
Mayo Clinic in Florida is now offering kidney and pancreas transplants to HIV positive patients with advanced kidney disease and diabetes. Evidence is now solid that HIV-positive patients have the same favorable outcome in ...

HIV racial disparities noted for men who have sex with men

July 20, 2012
(HealthDay) -- Similar racial disparities are seen in HIV infection for men who have sex with men (MSM) in the United States and the United Kingdom, according to a study published online July 20 in The Lancet.

Recommended for you

A new weapon against bone metastasis? Team develops antibody to fight cancer

December 11, 2017
In the ongoing battle between cancer and modern medicine, some therapeutic agents, while effective, can bring undesirable or even dangerous side effects. "Chemo saves lives and improves survival, but it could work much better ...

Insights on how SHARPIN promotes cancer progression

December 11, 2017
Researchers at Sanford Burnham Prebys Medical Discovery (SBP) and the Technion in Israel have found a new role for the SHARPIN protein. In addition to being one of three proteins in the linear ubiquitin chain assembly complex ...

Glioblastoma survival mechanism reveals new therapeutic target

December 11, 2017
A Northwestern Medicine study, published in the journal Cancer Cell, has provided new insights into a mechanism of tumor survival in glioblastoma and demonstrated that inhibiting the process could enhance the effects of radiation ...

Liver cancer: Lipid synthesis promotes tumor formation

December 11, 2017
Lipids comprise an optimal energy source and an important cell component. Researchers from the Biozentrum of the University of Basel and from the University of Geneva have now discovered that the protein mTOR stimulates the ...

Use of chemotherapy for early stage breast cancer declines, study says

December 11, 2017
A study of nearly 3,000 women with early stage breast cancer indicates a recent, significant decline in the use of chemotherapy despite the lack of any change in national treatment recommendations or guidelines, according ...

Researchers identify epigenetic orchestrator of pancreatic cancer cells

December 11, 2017
Genentech researchers have identified an enzyme that shifts pancreatic cancer cells to a more aggressive, drug-resistant state by epigenetically modifying the cells' chromatin. The study, which will be published December ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.